Skip to main content

The Gut-Liver Axis: the Main Role of Microbiome in Liver Diseases

Cover image for Research Topic "The Gut-Liver Axis: the Main Role of Microbiome in Liver Diseases"
111kviews
Editorial: The gut-liver axis: the main role of microbiome in liver diseases
Editorial11 March 2025
Editorial: The gut-liver axis: the main role of microbiome in liver diseases

It is clear that alteraBons in the composiBon of gut microbiota may contribute to the pathogenesis of liver diseases in mulBple ways by affecBng, among the others, gut permeability, immune response, and biliary salt metabolism [1]. Therefore, this special issue was launched to provide a broad spectrum perspecBve on new acquisiBons on microbiota involvement in the mulBfaceted field of liver diseases covering different condiBons from liver cirrhosis to autoimmune cholangiBs to NAFLD.Several arBcles of this special issue invesBgated the relevance of alteraBons in microbiota in the pathogenesis of NAFLD by using completely different experimental strategies. Lin et al. [2] used an animal model of the disease. They compared the intesBnal microbiome of 9 mice with NAFLD induced by a high fat diet with that of control mice and found that specific bacteria including Ileibacterium, Ruminococcaceae, Olsenella, Duncaniella, Paramuribaculum, Bifidobacterium and Coriobacteriaceae_UCG_002 were specifically associated with NAFLD. Different metabolic profiles also corresponded to the different composiBon of gut microbiome. UlBmately, the autors idenBfied a set of 8 bacterial strains, 14 genes and 83 metabolites, which strongly discriminate normal from NAFLD mice. By contrast, Pan et al. [3] used mendelian randomizaBon with published data obtained in humans to assess the causal relaBonship between the presence of specific bacterial strains in the gut with the development of NAFLD. The results of this analysis showed that 8 bacterial strains are strongly associated with this disease (the AcBnomycetales, NB1n, the family AcBnomycetaceae, Oxalobacteraceae and the genus Ruminococcaceae UCG005 were posiBvely correlated, whereas Lactobacillaceae, the Christensenellaceae R7 group, and Intes*nibacter were negaBvely correlated). Also in the analysis performed by Pan et al, differences in the microbiome corresponded to metabolic differences. The results were also validated in a mice model of NAFLD. A completely different approach was used by Shera et al. [4] who transplanted the feces from paBents who underwent bariatric surgery and, therefore, improved their NAFLD, into mice receiving high fat diet. This treatment significantly reduced the development of NAFLD in these mice and aZenuated the changes in the paZern of cytokine and T-lymphocytes characterisBcally associated with this disease.NAFLD may progress to NASH (nonalcoholic steatohepaBBs), which is characterized by significant liver inflammaBon and may progress to cirrhosis. The reason why this progression takes place in some paBents but not in others is largely unknown, but the data reported by Huang et al. [5] in this special issue point to microbiota composiBon as a key factor. They found, in fact, that Megamonas and Fusobacterium were significantly enriched in the fecal microbiome of NASH paBents in comparison with control subjects and NAFLD paBents. KEGG pathway analysis unveiled major metabolic differences in gut microbiota from NAFLD and NASH paBents.The relevance of changes in microbiota in the pathogenesis of liver cirrhosis was invesBgated in the arBcle by Li et al. [6] who compared the composiBon of microbiota and mycobiota in 45 cirrhoBc paBents and in 30 healthy controls. DisBncBve alteraBons were idenBfied since, in cirrhoBc paBents, Streptococcus, Akkermansia, Ligilactobacillus, Pseudescherichia were increased whereas Blau*a, Anaerobutyricum, Gemmiger, Ruminococcus, and Dorea were decreased. The major changes in mycobiota were an increase in Saccharomyces with a parallel decrease in Aspergillus, Penicillium, Auricularia, and Cladosporium. By combining, metagenomic data with the results of metabolomic analyses the authors developed a diagnosBc tesBng system which was able to idenBfy cirrhoBc paBents with a high accuracy (AUC of 0.938 at the ROC analysis).In the two arBcles by Cui et al. [7] and Zhang et al. [8] the associaBon between changes in gut microbiome and autoimmune liver diseases (was assessed by using mendelian randomizaBon (primary biliary cholangiBs and primary sclerosing cholangiBs).Natural products have been claimed to exert beneficial effect in liver diseases which can depend at least in part on changes in gut microbiota composiBon. Data in support of this hypothesis has been reported in two arBcles of this special issue. Sun et al. [9] reviewed the evidence that some tradiBonal Chinese medicine remedies, claimed to be effecBve in liver cirrhosis, could be acBng not only as anBoxidant, anBinflammatory and anB-fibroBc agents but also through modificaBons in gut microbiota. This has been shown for purified natural products used in tradiBonal Chinese medicine including polyphenols such as Resveratrol, Alkaloids such as Berberine, Terpenoids such as Ginko Biloba, Carbohydrates such as alginate, Glycosides such as FTA, a glycoside extracted from the dried fruit of Forsythia suspensa. Some evidence of beneficial changes in microbiota composiBon is also available for herbal prescripBons which contain mulBple compounds from different sources. Liang et al. [10] invesBgated the effect of licorice on the hepatoxicity of the Evodiae Fructus, a medicinal herb with analgesic, anB-tumor, and anB-inflammatory properBes. They showed that, in mice, the Evodiae Fructus, especially in the small-flowered forms, induces oxidaBve damage and inflammaBon in the liver and that these effects are aZenuated if the extract is given in combinaBon with licorice extracts. Changes in microbiota composiBon may contribute to licorice protecBve acBon. In fact, licorice prevented Evodiae Fructus-induced decrease in the abundance of Corynebacterium at the same Bme causing an increase in Candidatus Arthromitus. Importantly, the abundance of these two bacterial genera correlated respecBvely in a posiBve and negaBve way with biochemical markers of oxidaBve damage and inflammaBon. These results not only emphasize that natural products may protect the liver by modifying gut microbiota but also highlight that toxic substances may damage the liver in a microbiota-dependent manner. This concept was also addressed in the arBcle by TaranBno et al. [11] that explores the role of gut microbiota in the hepatotoxicity induced by drugs of abuse. The authors reviewed literature evidence showing that opioids alter the composiBon of intesBnal microbiota by inducing an increase in Gram-posiBve bacterial species such as Staphylococcus sciuri, Staphylococcus cohnii, and Staphylococcus aureus, as well as Enterococcus durans, Enterococcus casseliflavus, Enterococcus faecium, and Enterococcus faecalis. This opioid-induced dysbiosis causes the permeabilizaBon of the intesBnal barrier and, consequently, the translocaBon of bacterial species in the liver, which, in turn, is a strong inducer of inflammaBon and cell damage. Importantly, data are available to suggest that similar mechanisms also parBcipate in alcohol-induced hepatotoxicity. If the hypothesis that gut dysbiosis has an important role in the pathogenesis of alcohol-induced liver damage is correct, then it could be suggested that intervenBons aiming to modify the composiBon of intesBnal microbiota could be beneficial for this condiBon. This has been explored by Wei et al [12] who showed that alcohol feeding causes gut dysbiosis in mice by increasing the abundance of Oscillibacter, Escherichia/Shigella, and Alis*pes and a parallel increase in liver T-helper (Th) 1 and Th17 lymphocytes which is accompanied by a decrease in Treg. These changes were all reverted by the combined administraBon of Akkermansia muciniphila and of inosine, a compound which acts as an energy source and is also provided with anBnflammatory and immunomodulatory effects. Remarkably, this combined treatment promoted the growth of butyrateproducing bacteria including not only Akkermansia, but also Lactobacillus, and Clostridium IV.The molecular mechanisms by which intesBnal microorganisms may exert beneficial or detrimental effect on the liver have been extensively invesBgated and crucial factors have been idenBfied including bacterial translocaBon and endotoxin release, the release of indole and trimethylamine, bacterial metabolism o biliary acids and changes in the level of short chain faZy acids (Fig. 1). The arBcle by Sun et al. [13] describes a new potenBal mechanism for liver protecBon by gut microbiome. By using quadrupole Bme-of-flight mass spectrometry (Q-TOF-MS)-based metabolomics they showed that, in mice, steroid hormone biosynthesis liver regeneraBon ajer parBal hepatectomy is accompanied by a substanBal increase in liver steroid hormone biosynthesis possibly related to the observed increase in Escherichia, Shigella, Lactobacillus, Akkermansia, and Muribaculaceae in gut microbiome. In conclusion, with this research topic we aimed at improving our understanding of the potenBal mechanisms explaining the connecBon between gut flora dysbiosis and liver damage. The 16 publicaBons gathered in this Research Topic have expanded our knowledge about the role of the microbiome and its involvement in liver diseases. It remains to further explore the hypothesis that modifying the composiBon of gut microbiota with probioBcs/prebioBcs/symbioBcs such liver diseases could be ameliorated or prevented.

2,722 views

3 citations

Could chronic opioid use be an additional risk of hepatic damage in patients with previous liver diseases, and what is the role of microbiome?
Summary: Among illicit drugs, addiction from opioids and synthetic opioids is soaring in an unparalleled manner with its unacceptable amount of deaths. Apart from these extreme consequences, the liver toxicity is another important aspect that should be highlighted. Accordingly, the chronic use of these substances, of which fentanyl is the most frequently consumed, represents an additional risk of liver damage in patients with underlying chronic liver disease. These observations are drawn from various preclinical and clinical studies present in literature. Several downstream molecular events have been proposed, but recent pieces of research strengthen the hypothesis that dysbiosis of the gut microbiota is a solid mechanism inducing and worsening liver damage by both alcohol and illicit drugs. In this scenario, the gut flora modification ascribed to non-alcoholic fatty liver disease performs an additive role. Interestingly enough, HBV and HCV infections impact gut–liver axis. In the end, the authors tried to solicit the attention of operators on this major healthcare problem.

7,608 views

6 citations

Cirrhosis, a pathological stage that develops from various chronic liver diseases, is characterized by liver fibrosis, pseudolobular formation, and chronic inflammation. When it progresses to the decompensated phase, the mortality rate of cirrhosis can reach 80%. The role of gut microbiota in the progression of liver diseases has received significant attention. Numerous studies have shown that regulating gut microbiota has significant therapeutic effects on preventing and reversing liver cirrhosis. This article reviewed the mechanisms by which gut microbiota influence liver cirrhosis, explaining the effective therapeutic effects of traditional Chinese medicine. Through multi-directional regulation involving signaling pathways, gut microbiota diversity, and restoration of intestinal barrier function, traditional Chinese medicine has been promising in ameliorating liver cirrhosis, providing treatment options and pharmacological guidance for the occurrence and development of liver cirrhosis.

7,870 views

11 citations

ORIGINAL RESEARCH
21 August 2024
The signatures and crosstalk of gut microbiome, mycobiome, and metabolites in decompensated cirrhotic patients
Yangjie Li, 7 more and Huiguo Ding

3,988 views

5 citations

Bariatric-induced microbiome changes alter MASLD development in association with changes in the innate immune system
ORIGINAL RESEARCH
9 August 2024
Bariatric-induced microbiome changes alter MASLD development in association with changes in the innate immune system
Simer Shera, 17 more and Tien S. Dong
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly 25% of the population and is the leading cause for liver-related mortality. Bariatric surgery is a wellknown treatment for MASLD and obesity. Understanding the fundamental mechanisms by which bariatric surgery can alter MASLD can lead to new avenues of therapy and research. Previous studies have identified the microbiome's role in bariatric surgery and in inflammatory immune cell populations. The host innate immune system modulates hepatic inflammation and fibrosis, and thus the progression of MASLD. The precise role of immune cell types in the pathogenesis of MASLD remains an active area of investigation. The aim of this study was to understand the interplay between microbiota composition post-bariatric surgery and the immune system in MASLD. Methods: Eighteen morbidly obese females undergoing sleeve gastrectomy were followed pre-and post-surgery. Stool from four patients, showing resolved MASLD post-surgery with sustained weight loss, was transplanted into antibiotic treated mice. Mice received pre-or post-surgery stool and were fed a standard or high-fat diet. Bodyweight, food intake, and physiological parameters were tracked weekly. Metabolic parameters were measured post-study termination. Results: The human study revealed that bariatric surgery led to significant weight loss (p>0.05), decreased inflammatory markers, and improved glucose levels six months post-surgery. Patients with weight loss of 20% or more showed distinct changes in blood metabolites and gut microbiome composition, notably an increase in Bacteroides. The mouse model confirmed surgery-induced microbiome changes to be a major factor in the reduction of markers and attenuation of MASLD progression. Mice receiving post-surgery fecal transplants had significantly less weight gain and liver steatosis compared to pre-surgery recipients. There was also a significant decrease in inflammatory cytokines interferon gamma, interleukin 2, interleukin 15, and mig. This was accompanied by alterations in liver immunophenotype, including an increase in natural killer T cells and reduction of Kupfer cells in the post-surgery transplant group Discussion: Our findings suggest surgery induced microbial changes significantly reduce inflammatory markers and fatty liver progression. The results indicate a potential causal link between the microbiome and the host immune system, possibly mediated through modulation of liver NKT and Kupffer cells.

4,303 views

18 citations

Multi-omics analysis of the biological mechanism of the pathogenesis of non-alcoholic fatty liver disease
ORIGINAL RESEARCH
26 July 2024
Multi-omics analysis of the biological mechanism of the pathogenesis of non-alcoholic fatty liver disease
Jie Lin, 10 more and Jing You
Background: Non-alcoholic fatty liver disease (NAFLD) is a type of liver metabolic syndrome.Employing multi-omics analyses encompassing the microbiome, metabolome and transcriptome is crucial for comprehensively eclucidating the biological processes underlying NAFLD.Methods: Hepatic tissue, blood and faecal samples were obtained from 9 NAFLD model mice and 8 normal control mice. Total faecal microbiota DNA was extracted, and 16S rRNA was amplified, to analyse alterations in the gut microbiota (GM) induced by NAFLD. Subsequently, diagnostic strains for NAFLD were screened , and their functional aspects were examined. Differential metabolites and differentially expressed genes were also screened, followed by enrichment analysis . Correlations between the differential microbiota and metabolites, as well as between the DEGs and differential metabolites were studied. A collinear network involving key genes-,microbiota-and metabolites was constructed.

5,958 views

22 citations

ORIGINAL RESEARCH
8 August 2024
Licorice processing involving functions of Evodiae Fructus on liver inflammation and oxidative stress are associated with intestinal mucosal microbiota
Xuejuan Liang, 3 more and Yanmei Peng

2,142 views

Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
REVIEW
3 June 2024
Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
Meilin Wei, 1 more and Genhua Huang

7,480 views

47 citations

ORIGINAL RESEARCH
4 April 2024
From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients
Furong Huang, 14 more and Xu Fengping
From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients
Gut microbiota play a pivotal role in the pathogenesis of Non-alcoholic fatty liver disease (NAFLD). However, there remains limited understanding regarding the characteristics and ecological alterations of gut microbial communities during the progression of Non-alcoholic fatty liver (NAFL) to Non-alcoholic steatohepatitis (NASH). To address this point, we comparatively analyzed the gut microbiota composition of NAFL and NASH to obtain the characteristics and differences of their intestinal gut microbiota. The healthy group (65 cases), NAFL group (64 cases), and NASH group (53 cases) were compared using 16S rRNA sequencing, random forest machine learning, and database validation. It was observed that the diversity of intestinal flora gradually decreased during the progression of NAFLD disease (p < 0.05). At the phylum level, both NAFL and NASH patients exhibited high abundances of Bacteroidetes and Fusobacteria, while Firmicutes had low abundances. At the genus level, there was a significant decrease in the expression of Prevotella in the NAFL group (AUC 0.738). Conversely, the AUC value for Megamonas and Fusobacterium combination in the NASH group was 0.769. KEGG pathway analysis revealed significant disturbances in multiple types of glucose metabolism in the NASH group compared to NAFL group, as well as a significantly inadequate function in flavonoid and flavonol biosynthesis. In conclusion, this study reveals specific microbiota characteristics and intestinal microecological changes in the progression of NAFL to NASH, paving the way for the study of new biomarkers and therapeutic targets for NAFLD.

5,034 views

26 citations

ORIGINAL RESEARCH
27 March 2024
Association between gut microbiota and autoimmune cholestatic liver disease, a Mendelian randomization study
YangLin Cui, 2 more and GuangYe Zhang

5,340 views

13 citations

ORIGINAL RESEARCH
20 March 2024
Symbiotic combination of Akkermansia muciniphila and inosine alleviates alcohol-induced liver injury by modulating gut dysbiosis and immune responses
Li Wei, 10 more and Lanman Xu
Symbiotic combination of Akkermansia muciniphila and inosine alleviates alcohol-induced liver injury by modulating gut dysbiosis and immune responses
Alcoholic liver disease (ALD) is exacerbated by disruptions in intestinal microecology and immune imbalances within the gut-liver axis. The present study assesses the therapeutic potential of combining Akkermansia muciniphila (A. muciniphila) with inosine in alleviating alcohol-induced liver injury. Male C57BL/6 mice, subjected to a Lieber-DeCarli diet with 5% alcohol for 4 weeks, served as the alcoholic liver injury model. Various analyses, including quantitative reverse transcription polymerase chain reaction (qRT-PCR), ELISA, immunochemistry, 16S rRNA gene sequencing, and flow cytometry, were employed to evaluate liver injury parameters, intestinal barrier function, microbiota composition, and immune responses. Compared to the model group, the A. muciniphila and inosine groups exhibited significantly decreased alanine aminotransferase, aspartate 2 aminotransferase, and lipopolysaccharide (LPS) levels, reduced hepatic fat deposition and neutrophil infiltration, alleviated oxidative stress and inflammation, and increased expression of intestinal tight junction proteins (Claudin-1, Occludin, and ZO-1). These effects were further pronounced in the A. muciniphila and inosine combination group compared to individual treatments. While alcohol feeding induced intestinal dysbiosis and gut barrier disruption, the combined treatment reduced the abundance of harmful bacteria (Oscillibacter, Escherichia/Shigella, and Alistipes) induced by alcohol consumption, promoting the growth of butyrate-producing bacteria (Akkermansia, Lactobacillus, and Clostridium IV). Flow cytometry revealed that alcohol consumption reduced T regulatory (Treg) populations while increasing those of T-helper (Th) 1 and Th17, which were restored by A. muciniphila combined with inosine treatment. Moreover, A. muciniphila and inosine combination increased the expression levels of intestinal CD39, CD73, and adenosine A2A receptor (A2AR) along with enhanced proportions of CD4 + CD39 + Treg and CD4 + CD73 + Treg cells in the liver and spleen. The A2AR antagonist KW6002, blocked the beneficial effects of the A. muciniphila and inosine combination on liver injury in ALD mice. This study reveals that the combination of A. muciniphila and inosine holds promise for ameliorating ALD by enhancing the gut ecosystem, improving intestinal barrier function, upregulating A2AR, CD73, and CD39 expression, modulating Treg cells functionality, and regulating the imbalance of Treg/Th17/Th1 cells, and these beneficial effects are partly A2AR-dependent.

11,627 views

27 citations

Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)
SYSTEMATIC REVIEW
14 March 2024
Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)
Xiaofei Zhu, 1 more and Xiaxia Pan
The gut-liver axis has emerged as a focal point in chronic liver disorders, prompting more research into the role of the gut microbiota in liver cirrhosis. In individuals with liver cirrhosis, changes in the structure and function of the gut microbiota are closely tied to clinical prognosis. However, there is a scarcity of bibliometric evaluations conducted in this particular field. This study is aiming to conduct a complete analysis of the knowledge structure and centers pertaining to gut microbiota in liver cirrhosis using bibliometric methods. Publications on gut microbiota and liver cirrhosis from 2001 to 2023 are sourced from the Web of Science Core Collection. For the bibliometric analysis, we employ VOSviewer, CiteSpace, and the R package "bibliometrix". Our study encompasses a comprehensive collection of 3109 articles originating from 96 countries, with notable contributions from leading nations such as the United States and China. The quantity of publications concerning the gut microbiota of liver cirrhosis rises annually.

5,873 views

18 citations

ORIGINAL RESEARCH
8 January 2024
Impact of gut microbiota on nonalcoholic fatty liver disease: insights from a leave-one-out cross-validation study
Tongtong Pan, 3 more and Yongping Chen

4,111 views

17 citations